Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy.

Advanced congestive heart failure (CHF) and chronic kidney disease (CKD) are characterized by increased angiotensin II (Ang II) levels and are often accompanied by significant skeletal muscle wasting that negatively impacts mortality and morbidity. Both CHF and CKD patients have respiratory muscle d...

Full description

Bibliographic Details
Main Authors: Bashir M Rezk, Tadashi Yoshida, Laura Semprun-Prieto, Yusuke Higashi, Sergiy Sukhanov, Patrice Delafontaine
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3262800?pdf=render
id doaj-28de6ce6118f464f834d0345c002d700
record_format Article
spelling doaj-28de6ce6118f464f834d0345c002d7002020-11-25T00:27:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0171e3027610.1371/journal.pone.0030276Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy.Bashir M RezkTadashi YoshidaLaura Semprun-PrietoYusuke HigashiSergiy SukhanovPatrice DelafontaineAdvanced congestive heart failure (CHF) and chronic kidney disease (CKD) are characterized by increased angiotensin II (Ang II) levels and are often accompanied by significant skeletal muscle wasting that negatively impacts mortality and morbidity. Both CHF and CKD patients have respiratory muscle dysfunction, however the potential effects of Ang II on respiratory muscles are unknown. We investigated the effects of Ang II on diaphragm muscle in FVB mice. Ang II induced significant diaphragm muscle wasting (18.7±1.6% decrease in weight at one week) and reduction in fiber cross-sectional area. Expression of the E3 ubiquitin ligases atrogin-1 and muscle ring finger-1 (MuRF-1) and of the pro-apoptotic factor BAX was increased after 24 h of Ang II infusion (4.4±0.3 fold, 3.1±0.5 fold and 1.6±0.2 fold, respectively, compared to sham infused control) suggesting increased muscle protein degradation and apoptosis. In Ang II infused animals, there was significant regeneration of injured diaphragm muscles at 7 days as indicated by an increase in the number of myofibers with centralized nuclei and high expression of embryonic myosin heavy chain (E-MyHC, 11.2±3.3 fold increase) and of the satellite cell marker M-cadherin (59.2±22.2% increase). Furthermore, there was an increase in expression of insulin-like growth factor-1 (IGF-1, 1.8±0.3 fold increase) in Ang II infused diaphragm, suggesting the involvement of IGF-1 in diaphragm muscle regeneration. Bone-marrow transplantation experiments indicated that although there was recruitment of bone-marrow derived cells to the injured diaphragm in Ang II infused mice (267.0±74.6% increase), those cells did not express markers of muscle stem cells or regenerating myofibers. In conclusion, Ang II causes marked diaphragm muscle wasting, which may be important for the pathophysiology of respiratory muscle dysfunction and cachexia in conditions such as CHF and CKD.http://europepmc.org/articles/PMC3262800?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Bashir M Rezk
Tadashi Yoshida
Laura Semprun-Prieto
Yusuke Higashi
Sergiy Sukhanov
Patrice Delafontaine
spellingShingle Bashir M Rezk
Tadashi Yoshida
Laura Semprun-Prieto
Yusuke Higashi
Sergiy Sukhanov
Patrice Delafontaine
Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy.
PLoS ONE
author_facet Bashir M Rezk
Tadashi Yoshida
Laura Semprun-Prieto
Yusuke Higashi
Sergiy Sukhanov
Patrice Delafontaine
author_sort Bashir M Rezk
title Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy.
title_short Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy.
title_full Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy.
title_fullStr Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy.
title_full_unstemmed Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy.
title_sort angiotensin ii infusion induces marked diaphragmatic skeletal muscle atrophy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description Advanced congestive heart failure (CHF) and chronic kidney disease (CKD) are characterized by increased angiotensin II (Ang II) levels and are often accompanied by significant skeletal muscle wasting that negatively impacts mortality and morbidity. Both CHF and CKD patients have respiratory muscle dysfunction, however the potential effects of Ang II on respiratory muscles are unknown. We investigated the effects of Ang II on diaphragm muscle in FVB mice. Ang II induced significant diaphragm muscle wasting (18.7±1.6% decrease in weight at one week) and reduction in fiber cross-sectional area. Expression of the E3 ubiquitin ligases atrogin-1 and muscle ring finger-1 (MuRF-1) and of the pro-apoptotic factor BAX was increased after 24 h of Ang II infusion (4.4±0.3 fold, 3.1±0.5 fold and 1.6±0.2 fold, respectively, compared to sham infused control) suggesting increased muscle protein degradation and apoptosis. In Ang II infused animals, there was significant regeneration of injured diaphragm muscles at 7 days as indicated by an increase in the number of myofibers with centralized nuclei and high expression of embryonic myosin heavy chain (E-MyHC, 11.2±3.3 fold increase) and of the satellite cell marker M-cadherin (59.2±22.2% increase). Furthermore, there was an increase in expression of insulin-like growth factor-1 (IGF-1, 1.8±0.3 fold increase) in Ang II infused diaphragm, suggesting the involvement of IGF-1 in diaphragm muscle regeneration. Bone-marrow transplantation experiments indicated that although there was recruitment of bone-marrow derived cells to the injured diaphragm in Ang II infused mice (267.0±74.6% increase), those cells did not express markers of muscle stem cells or regenerating myofibers. In conclusion, Ang II causes marked diaphragm muscle wasting, which may be important for the pathophysiology of respiratory muscle dysfunction and cachexia in conditions such as CHF and CKD.
url http://europepmc.org/articles/PMC3262800?pdf=render
work_keys_str_mv AT bashirmrezk angiotensiniiinfusioninducesmarkeddiaphragmaticskeletalmuscleatrophy
AT tadashiyoshida angiotensiniiinfusioninducesmarkeddiaphragmaticskeletalmuscleatrophy
AT laurasemprunprieto angiotensiniiinfusioninducesmarkeddiaphragmaticskeletalmuscleatrophy
AT yusukehigashi angiotensiniiinfusioninducesmarkeddiaphragmaticskeletalmuscleatrophy
AT sergiysukhanov angiotensiniiinfusioninducesmarkeddiaphragmaticskeletalmuscleatrophy
AT patricedelafontaine angiotensiniiinfusioninducesmarkeddiaphragmaticskeletalmuscleatrophy
_version_ 1725341383738261504